Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of K-134 in Intermittent Claudication
NCT00783081Phase 2Completed
- Start
- Nov 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of K-134 in intermittent claudication (IC) (5 arms). Primary endpoint: Peak Walking Time at 26 weeks. Started Nov 2008; status: completed.
02
Drugs
K-134
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT00783081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783081.